Recently, the Prescription Medicines Code of Practice Authority announced in a press release that 5 pharmaceutical companies have breached the Association of the British Pharmaceutical Industry’s Code of Practice.
Recently, the Prescription Medicines Code of Practice Authority (PMCPA) announced in a press release that 5 pharmaceutical companies have breached the Association of the British Pharmaceutical Industry’s (ABPI) Code of Practice. The code reflects and extends beyond UK law, and is administered by the PMCPA as part of a self-regulatory system that covers prescription medicines.
PMCPA publicly reprimanded Sunovion Pharmaceuticals Europe LTD for allowing 1 of its managers to encourage staff to suggest to customers that they could face legal action if they did not consider lurasidone (Latuda) as part of a patient review. It was ruled that Sunovion was in breach for failing to maintain a high standard of ethical conduct in the field, and for providing verbal direction that advocated a course of action that would lead to a breach of the Code. The public reprimand appears on the front cover of the PMCPA November 2017 Code of Practice Review. Subsequently, the Code of Practice Appeal Board also required Sunovion to be audited.
Additionally, all of the following companies were cited for, among other issues, bringing discredit to and reducing confidence in the pharmaceutical industry:
The full case reports are published in the PMCPA November 2017 Code of Practice Review, and are also available at www.pmcpa.org.uk.
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
November 9th 2024A review article on tumor necrosis factor (TNF)-α inhibitors in inflammatory bowel disease (IBD) outlined current use of anti-TNF originators and biosimilars, their efficacy and safety, the benefits and challenges of biosimilars, and the future of biosimilars in IBD.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Panelists Stress Stakeholder Education to Build Confidence in Biosimilars
October 31st 2024By expanding educational initiatives to clarify biosimilar safety, efficacy, and interchangeability, stakeholders can foster trust, improve access, and ensure that biosimilars are widely accepted as high-quality, cost-effective alternatives to originator biologics.
Enhancing Adoption of Infused Biosimilars for a Sustainable Future
October 30th 2024An IQVIA report highlights challenges to the sustainability of infused biosimilars in the US, citing rebate walls and reimbursement policies, and proposes key solutions to enhance adoption and benefits for all stakeholders.